Novus Therapeutics

52 articles about Novus Therapeutics

• Novus Therapeutics Announces Name Change to Eledon Pharmaceuticals; Provides Corporate Update and Outlook

  1/4/2021

  Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons living with an autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today provided a corporate update and offered its outlook for 2021 and beyond.

• Novus Therapeutics Announces Results of Special Meeting of Stockholders

  12/22/2020

  Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced results from a special meeting of stockholders that was held on Friday, December 19, 2020. During the meeting, Novus’ stockholders approved a proposal for the issuance

• 

  Advances in the Battle Against Autoimmune Disease

  12/16/2020

  Many drug makers are investing in new science and hope to develop new therapeutics that address autoimmune disease. BioSpace has captured some key efforts.

• Novus Therapeutics Appoints June Lee, M.D., to Board of Directors

  12/9/2020

  Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced the appointment of June Lee, M.D., to the company’s Board of Directors.

• Novus Therapeutics Reports Third Quarter 2020 Financial Results

  11/16/2020

  Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today reported its financial results for the quarter ended September 30, 2020, and operationa

• Novus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16

  11/10/2020

  Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that the company will report its financial results for the three

• Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis

  11/2/2020

  Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that the first subject has been enrolled in the Phase 2a clinical trial evaluating AT-1501, the Company’s lead product candidate, in adults with amy

• Lineage Cell Therapeutics to Host Expert Call Following OpRegen® Data Update at 2020 American Academy of Ophthalmology Meeting

  11/2/2020

  Lineage Cell Therapeutics to Host Expert Call Following OpRegen ® Data Update at 2020 American Academy of Ophthalmology Meeting KOL Call with Principal Investigator Christopher D. Riemann, M.D., Scheduled for November 17, 2020 at 4:00 pm Eastern Time

• Novus Therapeutics Announces One-for-Eighteen Reverse Stock Split

  10/2/2020

  Novus Therapeutics, Inc. (NASDAQ : NVUS) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-18.

• 

  BioSpace Movers & Shakers, Sept. 18

  9/18/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
• 

  Novus Finalizes Acquisition of Anelixis to Further Develop AT-1501

  9/16/2020

  Novus Therapeutics announced on Monday that it had completed its acquisition of Anelixis Therapeutics, a privately held clinical stage biotechnology company.

• Novus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment Conferences

  9/15/2020

  Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will present a corporate overview to virtual audiences this week at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference

• Novus Therapeutics Announces Acquisition of Anelixis Therapeutics

  9/14/2020

  Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS) today announced it has completed the acquisition of Anelixis Therapeutics, Inc. (“Anelixis”), a privately held clinical stage biotechnology company developing a next generation anti-CD40 Ligand (CD40L) antibody as a potential treatment for organ and cellular transplantation, autoimmune diseases, and neurodegenerative diseases

• 

  Clinical Catch-Up: May 31-June 5

  6/8/2020

  As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.
• 

  After Failure of Earache Drug, Novus Therapeutics Seeks Strategic Alternatives

  6/2/2020

  Novus Therapeutics announced that its Phase IIa clinical trial of OPO201 in acute otitis media, or inflammation of the middle ear, failed to meet its primary endpoint.

• Novus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media

  6/1/2020

  Resolution of middle ear effusion in 56% of OP0201 vs. 38% of placebo patients (p=0.07) Company engages financial advisors to explore strategic options IRVINE, Calif.--( BUSINESS WIRE )-- Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced topline results from the company’s exploratory phase 2a clinical trial of

• Novus Therapeutics Reports First Quarter 2020 Financial Results

  5/15/2020

  Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced financial results for the quarter ended March 31, 2020. Operational Highlights Raised gross proceeds of approximately $5.8 million through the exercise of outstanding warrants in January 2020 Completed enrollment of OP0201

• Novus Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results

  3/17/2020

  Novus Therapeutics, Inc. today announced financial results for the fourth quarter and full-year ended December 31, 2019. “We made stea

• Novus Therapeutics Completes Enrollment of Phase 2a Trial of OP0201 in Pediatric Patients with Acute Otitis Media

  3/2/2020

  Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced that it has completed enrollment of the phase 2a trial of OP0201 in pediatric patients with acute otitis media (study C-006).

• Novus Therapeutics Provides Update on OP0201

  1/13/2020

  Phase 2a study C-006 enrollment to be completed in 1Q 2020; data expected in 2Q 2020